2021-04-27 by Proactive Australia MGC Pharmaceuticals Ltd (ASX:MXC)(LON:MXC)(OTCMKTS:MGCLF)(FRA:H5O) has completed arguably its best-ever quarter, with a London Stock Exchange (LSE) listing and record sales highlighting a busy period. The European-based biopharma company, developing and producing phytocannabinoid-derived medicines, released its March quarterly report this morning. It also gained Ethics Committee approval for a Phase III trial to evaluate the efficacy and safety of its COVID-19 drug, CimetrA TM, expanded its pre-clinical brain cancer study and locked in additional funding. Break-even on the horizon MGC CEO Roby Zomer told investors the company was now ready to capitalise on years of hard work.